← All trials
NCT00560222
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2008
- Primary completion
- May 31, 2011
- Completion date
- Oct 31, 2011
- First posted
- Nov 19, 2007
- Last posted
- Nov 1, 2011
- Enrollment
- 555
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institutes of Health (NIH)Lead sponsor
- National Institutes of Health (NIH)Reponsible party - principal investigator
- University of Texas at HoustonOfficial
- National Institutes of Health (NIH)Sponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.